Lupin hits 52-week low on weak Q4 numbers
Nidhi Jani / 24 May 2017
The company reported PAT of Rs 380 crore, which represents a sequential QoQ decline of 40 per cent and a YoY decline of 49 per cent.
Lupin reported its results for the quarter ended March 31, 2017 on Wednesday.
The company's total sales for Q4FY17 came in at Rs 4161.8 crore, which represents a 5.5 per cent sequential decline and 1.3 per cent YoY increase.
Its operating profit (EBIT) for the quarter amounted to Rs 422.5 crore and its EBIT margin stood at 10.2 per cent.
The company reported PAT of Rs 380 crore, which represents a sequential QoQ decline of 40 per cent and a YoY decline of 49 per cent.
The stock opened today at Rs 1250 and touched its 52-week low of Rs 1168.10 on the BSE.
The board of directors has recommended dividend of Rs 7.5 per equity share on the face value of Rs 2 each.
Lupin is engaged in production of wide range of affordable generic and branded formulations and APIs (active pharmaceutical ingredients). The company focuses on tuberculosis drugs, cardiovascular (prils and statins), diabetology, asthma, paediatrics, CNS, GI, anti-infective and NSAIDS therapy segments.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.